Showing results (501-510 of 565) with videos related to
Sort By:
Pageof 57
Inflammatory Bowel Diseases|May 2, 2009
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximabWaqqas Afif, Jonathan A Leighton, Stephen B Hanauer, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 22, 2021
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI TrialWilliam J Sandborn, Rory Rebuck, Yuhua Wang, et al.Gastroenterology|July 5, 2011
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitisJean Frédéric Colombel, Paul Rutgeerts, Walter Reinisch, et al.Inflammatory Bowel Diseases|December 22, 2023
The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated DiseaseAkhilesh Swaminathan, James M Fulforth, Chris M Frampton, et al.Gastroenterology|July 15, 2009
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximabWilliam J Sandborn, Paul Rutgeerts, Brian G Feagan, et al.Therapeutic Advances in Gastroenterology|October 13, 2025
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysisMarc Ferrante, Laurent Peyrin-Biroulet, Perttu Arkkila, et al.Journal of Crohn'S & Colitis|September 22, 2023
Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A Prospective Open-label StudyGeert D'Haens, Michael Eberhardson, Zeljko Cabrijan, et al.The New England Journal of Medicine|September 29, 2021
Ozanimod as Induction and Maintenance Therapy for Ulcerative ColitisWilliam J Sandborn, Brian G Feagan, Geert D'Haens, et al.Inflammatory Bowel Diseases|November 22, 2025
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by AgeAdam S Faye, David T Rubin, Corey A Siegel, et al.Nature Medicine|February 24, 2023
Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel diseaseRaaj S Mehta, Jared R Mayers, Yancong Zhang, et al.Pageof 57